Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 4, 2008, Pages 925-931

  Chen, Chun Hsin ^a,b   Chiu, Chih Chiang ^a,c,d   Huang, Ming Chyi ^a,c   Wu, Tzu Hua ^e   Liu, Hui Ching ^f   Lu, Mong Liang ^a,b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e School of Pharmacy   (Taiwan)

^f Hung Chi Psychiatric Hospital   (Taiwan)

Author keywords

Insulin resistance; Metabolic syndrome; Metformin; Olanzapine; Schizophrenia

Indexed keywords

INSULIN; METFORMIN; OLANZAPINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; MALE; METABOLIC DISORDER; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MULTICENTER STUDY; SCHIZOPHRENIA;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; BODY WEIGHT; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; METABOLIC DISEASES; METABOLIC SYNDROME X; METFORMIN; MIDDLE AGED; PROSPECTIVE STUDIES; SCHIZOPHRENIA; SEX CHARACTERISTICS;

EID: 42949110123     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.11.013     Document Type: Article

References (49)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156 (1999) 1686-1696
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fourth ed. (1994), American Psychiatric Association, Washington, DC
3. Arranz B., Rosel P., Ramírez N., Dueñas R., Fernández P., Sanchez J.M., et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 65 (2004) 1335-1342
4. Baptista T., Hernandez L., Prieto L.A., Boyero E.C., and de Mendoza S. Metformin in obesity associated with antipsychotic drug administration: a pilot study. J Clin Psychiatry 62 (2001) 653-655
5. Baptista T., Kin N.M., Beaulieu S., and de Baptista E.A. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35 (2002) 205-219
6. Baptista T., Martinez J., Lacruz A., Rangel N., Beaulieu S., Serrano A., et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry 51 (2006) 192-196
7. Baptista T., Rangel N., Fernandez V., Carrizo E., El Fakih Y., Uzcategui E., et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res 93 (2007) 99-108
8. Baptista T., Sandia I., Lacruz A., Rangel N., de Mendoza S., Beaulieu S., et al. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. Int Clin Psychopharmacol 22 (2007) 69-76
9. Baptista T., Dávila A., El Fakih Y., Uzcátegui E., Rangel N.N., Olivares Y., et al. Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia. Int Clin Psychopharmacol 22 (2007) 205-211
10. Bergman R.N., and Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev 6 (1985) 45-86
11. Bergman R.N., and Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 66 (2005) 504-514
12. Bushe C., Haddad P., Peveler R., and Pendlebury J. The role of lifestyle interventions and weight management in schizophrenia. J Psychopharmacol 19 (2005) 28-35
13. Casey D.E., Haupt D.W., Newcomer J.W., Henderson D.C., Sernyak M.J., Davidson M., et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 65 Suppl 7 (2004) 4-18
14. Charles M.A., Eschwege E., Grandmottet P., Isnard F., Cohen J.M., Bensoussan J.L., et al. Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial. Diabetes Metab Res Rev 16 (2000) 2-7
15. Ciudad A., Gutierrez M., Canas F., Gibert J., Gascon J., Carrasco J.L., et al. Safety and effectiveness of olanzapine in monotherapy: a multivariate analysis of a naturalistic study. Prog Neuro-Psychopharmacol Biol Psychiatry 29 (2005) 944-951
16. Duijnhoven E.M., Boots J.M., Christiaans M.H., Wolffenbuttel B.H., and Van Hooff J.P. Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol 12 (2001) 583-588
17. Elman I., Borsook D., and Lukas S.E. Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology 31 (2006) 2091-2120
18. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
19. Glueck C.J., Fontaine R.N., Wang P., Subbiah M.T., Weber K., Illig E., et al. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 50 (2001) 856-861
20. Glueck C.J., Aregawi D., Agloria M., Winiarska M., Sieve L., and Wang P. Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome. Metabolism 55 (2006) 1582-1589
21. Goff D.C., Cather C., Evins A.E., Henderson D.C., Freudenreich O., Copeland P.M., et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 66 (2005) 183-194
22. Gómez J.M. Serum leptin, insulin-like growth factor-I components and sex-hormone binding globulin. Relationship with sex, age and body composition in healthy population. Prot Peptide Letters 14 (2007) 708-711
23. Guy W. Clinical global impression, ECDEU assessment manual for psychopharmacology, revised (1976), National Institute of Mental Health, Rockville, MD
24. Harris E.C., and Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 173 (1998) 11-53
25. Heiskanen T., Niskanen L., Lyytikainen R., Saarinen P.I., and Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 64 (2003) 575-579
26. Hundal R.S., and Inzucchi S.E. Metformin: new understandings, new uses. Drugs 63 (2003) 1879-1894
27. Hwang L.C., Bai C.H., and Chen C.J. Prevalence of obesity and metabolic syndrome in Taiwan. J Formos Med Assoc 105 (2006) 626-635
28. Jin H., Meyer J.M., and Jeste D.V. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res 71 (2004) 195-212
29. Kay J.P., Alemzadeh R., Langley G., D'Angelo L., Smith P., and Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 50 (2001) 1457-1461
30. Kelleher J.P., Centorrino F., Albert M.J., and Baldessarini R.J. Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents. CNS Drugs 16 (2002) 249-261
31. Klein D.J., Cottingham E.M., Sorter M., Barton B.A., and Morrison J.A. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 163 (2006) 2072-2079
32. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
33. Lambert M.T., Copeland L.A., Sampson N., and Duffy S.A. New-onset type-2 diabetes associated with atypical antipsychotic medications. Prog Neuro-Psychopharmacol Biol Psychiatry 30 (2006) 919-923
34. Lehtovirta M., Kaprio J., Groop L., Trombetta M., and Bonadonna R.C. Heritability of model-derived parameters of beta cell secretion during intravenous and oral glucose tolerance tests: a study of twins. Diabetologia 48 (2005) 1604-1613
35. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., and Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334 (1987) 1-100
36. Loh C., Meyer J.M., and Leckband S.G. A comprehensive review of behavioral interventions for weight management in schizophrenia. Ann Clin Psychiatry 18 (2006) 23-31
37. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
38. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80 (2005) 19-32
39. McKibbin C.L., Patterson T.L., Norman G., Patrick K., Jin H., Roesch S., et al. A lifestyle intervention for older schizophrenia patients with diabetes mellitus: a randomized controlled trial. Schizophr Res 86 (2006) 36-44
40. Melkersson K., and Dahl M.L. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 64 (2004) 701-723
41. Morrison J.A., Cottingham E.M., and Barton B.A. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 159 (2002) 655-657
42. Newcomer J.W. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 65 Suppl 18 (2004) 36-46
43. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 Suppl 1 (2005) 1-93
44. Orchard T.J., Temprosa M., Goldberg R., Haffner S., Ratner R., Marcovina S., et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 142 (2005) 611-619
45. Pasanisi F., Contaldo F., de Simone G., and Mancini M. Benefits of sustained moderate weight loss in obesity. Nutr Metab Cardiovasc Dis 11 (2001) 401-406
46. Simpson J.C., and Tsuang M.T. Mortality among patients with schizophrenia. Schizophr Bull 22 (1996) 485-499
47. Sivitz W.I., Wayson S.M., Bayless M.L., Larson L.F., Sinkey C., Bar R.S., et al. Leptin and body fat in type 2 diabetes and monodrug therapy. J Clin Endocrinol Metab 88 (2003) 1543-1553
48. Tan C.E., Ma S., Wai D., Chew S.K., and Tai E.S. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?. Diabetes Care 27 (2004) 1182-1186
49. Velazquez E.M., Mendoza S., Hamer T., Sosa F., and Glueck C.J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43 (1994) 647-654